Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
Director departure
Appointed director
CC transcript
|
|
FOXO TECHNOLOGIES INC.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 08/23/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E... |
| 08/18/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
8-K
| Unregistered Sales of Equity Securities, Financial Statements and Exhibits Interactive Data |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/20/2023 |
8-K
| Quarterly results |
| 06/16/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure... |
| 05/30/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/17/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure... |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"FOXO Technologies™ Announces First Quarter 2023 Financial Results MINNEAPOLIS, MN, MAY 11, 2023 — FOXO Technologies Inc. , a leader in commercializing epigenetic biomarkers of health and aging, today reported financial results for the first quarter ended March 31, 2023. “The first quarter was a strong start to the year, and I am very pleased by our continued execution in support of our strategic goals,” said Tyler Danielson, interim CEO and Chief Technology Officer of FOXO. “We recently announced the launch of our direct-to-consumer FOXO Longevity Report™ beta, which represents the next stage in FOXO’ s evolution and expands on our successes in the insurance market. We believe this significant milestone will serve to improve the scale of our customer engagement platform while e..." |
|
| 04/18/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/31/2023 |
8-K
| Conference call transcript|
Docs:
|
"FOXO Technologies™ Announces Full Year 2022 Financial Results and Recent Business Highlights MINNEAPOLIS, MN, MARCH 30, 2023 — FOXO Technologies Inc. , a leader in commercializing epigenetic biomarkers of health and aging in life insurance, today reported financial results for the full year ended December 31, 2022 and accompanying business highlights. “I am truly excited with the future we are building,” said Tyler Danielson, interim CEO and Chief Technology Officer of FOXO. “The challenges faced in 2022 presented us with an opportunity to take a comprehensive assessment of our business and the way we approach the market. We sought to reset our vision and mission, and identify the clear objectives that we believe are necessary to achieve them and hold ourselves accountable. Our aim i...",
"Transcript of Conference Call held on March 30, 2023" |
|
| 03/20/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/08/2023 |
8-K
| Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits Interactive Data |
| 02/03/2023 |
8-K
| Quarterly results |
| 02/02/2023 |
8-K
| Resignation/termination of a director |
| 01/12/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 11/15/2022 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Departure of Directors or Certain... |
| 09/26/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 09/21/2022 |
8-K
| Director compensation was amended/approved, Appointed a new director|
Docs:
|
"CERTIFICATE OF INCORPORATION OF FOXO TECHNOLOGIES INC",
"BYLAWS OF FOXO TECHNOLOGIES INC",
"FORM OF ASSUMED WARRANT",
"FORM OF 15% SENIOR PROMISSORY NOTE",
"FOXO TECHNOLOGIES INC. 2022 EQUITY INCENTIVE PLAN",
"FOXO TECHNOLOGIES INC. 2020 EQUITY INCENTIVE PLAN",
"FORM OF FOXO TECHNOLOGIES INC. 2020 EQUITY INCENTIVE PLAN AWARD AGREEMENTS",
"Recitals",
"FORM OF REVISED BACKSTOP SUBSCRIPTION AGREEMENT, DATED SEPTEMBER 13, 2022",
"INSIDER LETTER AMENDMENT" |
|
| 09/16/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 09/13/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/12/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/06/2022 |
8-K
| Quarterly results |
| 06/07/2022 |
8-K
| Quarterly results |
| 03/02/2022 |
8-K
| Quarterly results |
| 02/25/2022 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Regulation...|
Docs:
|
"PROMISSORY NOTE Principal Amount: Up to $2,000,000.00 Dated as of February 23, 2022 New York, New York Delwinds Insurance Acquisition Corp., a Delaware corporation , promises to pay to the order of DIAC Sponsor LLC, a Delaware limited liability company, or its registered assigns or successors in interest , or order, the principal sum of up to Two Million Dollars in lawful money of the United States of America, on the terms and conditions described below. All payments on this Note shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as Payee may from time to time designate by written notice in accordance with the provisions of this Note. 1. Repayment. The principal balance of this Note shall be payable on the earliest...",
"INVESTOR DECK",
"SCRIPT TO INVESTOR PRESENTATION",
"MODERNIZING UNDERWRITING WITH EPIGENTICS AND MACHINE LEARNING According to LIMRA International, Inc., an international research association for life insurance and financial services companies, among the most significant current issues in the life insurance industry are the lengthy timelines and invasive blood and urine specimen requirements associated with underwriting. FOXO is at the forefront of commercializing proprietary saliva-based epigenetic biomarkers with a plan to create a simpler, smoother, non-invasive underwriting process. FOXO expects its seamless saliva based underwriting process to provide enhanced protective value and represent a step-change improvement to the global life insurance industry. FOXO’ s proprietary epigenetic biomarker technology is designed to address the sam..." |
|
| 05/07/2021 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review |
| 01/26/2021 |
8-K
| Quarterly results |
| 12/21/2020 |
8-K
| Other Events, Financial Statements and Exhibits |
| 12/16/2020 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...|
Docs:
|
"Underwriting Agreement, by and among the Company, RBC Capital Markets, LLC and Cantor Fitzgerald & Co",
"Amended and Restated Certificate of Incorporation",
"Warrant Agreement, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent",
"Letter Agreement, by and among the Company, its officers and directors and the Sponsor",
"Investment Management Trust Agreement, by and between the Company and Continental Stock Transfer & Trust Company, as trustee",
"Registration Rights Agreement, by and among the Company and certain security holders",
"Private Placement Unit Purchase Agreement, by and between the Company and the Sponsor",
"Administrative Services Agreement, by and between the Company and the Sponsor",
"Delwinds Insurance Acquisition Corporation Announces Pricing of",
"Delwinds Insurance Acquisition Corp. Announces Closing of" |
|
|
|